These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10428260)

  • 21. Insulin requirement after a renal transplant in patients with type 2 diabetes: the choice of calcineurin inhibitors.
    van den Hoogen MW; van der Hoeven AM; Hilbrands LB
    Exp Clin Transplant; 2013 Jun; 11(3):234-8. PubMed ID: 23432070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improvement of drug-induced chronic renal failure in lung transplantation.
    Soccal PM; Gasche Y; Favre H; Spiliopoulos A; Nicod LP
    Transplantation; 1999 Jul; 68(1):164-5. PubMed ID: 10428288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sirolimus as primary immunosuppressant for calcineurin inhibitor-related renal insufficiency after liver transplantation.
    Yang YJ; Li LX; He Q; Fan H; Jin ZK; Lang R; Kou JT; Li P; Xie DH; Chen DZ
    Hepatobiliary Pancreat Dis Int; 2007 Aug; 6(4):376-8. PubMed ID: 17690032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimization of the use of Calcineurin inhibitors in liver transplantation.
    de Mare-Bredemeijer EL; Metselaar HJ
    Best Pract Res Clin Gastroenterol; 2012 Feb; 26(1):85-95. PubMed ID: 22482528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conversion from cyclosporine to tacrolimus in renal allograft recipients with chronic graft nephropathy: preliminary report.
    Morris-Stiff G; Baboolal K; Singh J; Balaji V; Ostrowski K; Moore R; Lord R; Jurewicz A
    Transplant Proc; 1998 Jun; 30(4):1245-6. PubMed ID: 9636506
    [No Abstract]   [Full Text] [Related]  

  • 26. Cryptococcus neoformans isolates from transplant recipients are not selected for resistance to calcineurin inhibitors by current immunosuppressive regimens.
    Blankenship JR; Singh N; Alexander BD; Heitman J
    J Clin Microbiol; 2005 Jan; 43(1):464-7. PubMed ID: 15635017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of calcineurin inhibitors on paraoxonase and arylesterase activity after a kidney transplant.
    Kahvecioglu S; Ersoy A; Gullulu M; Dirican M
    Exp Clin Transplant; 2014 Aug; 12(4):334-42. PubMed ID: 24447269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune monitoring with a lymphocyte adenosine triphosphate assay in kidney transplant recipients treated with a calcineurin inhibitor.
    Sugiyama K; Tsukaguchi M; Toyama A; Satoh H; Saito K; Nakagawa Y; Takahashi K; Tanaka S; Onda K; Hirano T
    Exp Clin Transplant; 2014 Jun; 12(3):195-9. PubMed ID: 24907718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Interaction between sildenafil and calcineurin inhibitors in renal transplant recipients with erectile dysfunction].
    Cofán F; Gutiérrez R; Beardo P; Campistol JM; Oppenheimer F; Alcover J
    Nefrologia; 2002; 22(5):470-6. PubMed ID: 12497749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The CARI guidelines. Calcineurin inhibitors in paediatric renal transplantation.
    McTaggart S;
    Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S106-10. PubMed ID: 17316270
    [No Abstract]   [Full Text] [Related]  

  • 31. Low-density lipoprotein composition and oxidation are not influenced by calcineurin inhibitors in renal transplant patients.
    Morena M; Vela C; Garrigue V; Catanzano J; Descomps B; Cristol JP; Mourad G
    Transplant Proc; 2000 Dec; 32(8):2785-6. PubMed ID: 11134805
    [No Abstract]   [Full Text] [Related]  

  • 32. Immunosuppressive agents and metabolic factors of cardiovascular risk in renal transplant recipients.
    Sessa A; Esposito A; Giliberti A; Iavicoli G; Costa C; Bergallo M; Lettieri E; Rossano R; Capuano M
    Transplant Proc; 2009 May; 41(4):1178-82. PubMed ID: 19460510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative study of the cellular pharmacodynamics of calcineurin inhibitors between patients with chronic renal failure awaiting renal transplantation and cirrhosis patients awaiting liver transplantation.
    Kihara Y; Matsuno N; Mijiti A; Nagao T; Takeuchi H; Unezaki S; Hirano T
    Cell Transplant; 2009; 18(5):639-46. PubMed ID: 19775526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Controversies about the use of calcineurin inhibitors in pediatric patients].
    Dello Strologo L
    G Ital Nefrol; 2008; 25(3):317-24. PubMed ID: 18473303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methods and outcomes of calcineurin inhibitor reduction or withdrawal in patients with chronic allograft nephropathy after the first year posttransplantation.
    Weir MR
    Transplant Proc; 2001 Jun; 33(4 Suppl):19S-28S. PubMed ID: 11406264
    [No Abstract]   [Full Text] [Related]  

  • 36. Nephrotoxicity associated with cyclosporine and FK506.
    Klintmalm GB; Gonwa TA
    Liver Transpl Surg; 1995 Sep; 1(5 Suppl 1):11-9. PubMed ID: 9346596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The CARI guidelines. Choice of calcineurin inhibitors in adult renal transplantation: effects on transplant outcomes.
    Pilmore H;
    Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S88-97. PubMed ID: 17316287
    [No Abstract]   [Full Text] [Related]  

  • 38. Monitoring calcineurin inhibitor therapy: localizing the moving target.
    Naesens M; Sarwal MM
    Transplantation; 2010 Jun; 89(11):1308-9. PubMed ID: 20458272
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus.
    Fuchs U; Zittermann A; Ensminger SM; Schulz U; Gummert JF
    Transpl Immunol; 2014 Aug; 31(2):87-91. PubMed ID: 24932812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sirolimus and cyclosporin for renal transplantation.
    Halloran PF
    Lancet; 2000 Jul; 356(9225):179-80. PubMed ID: 10963190
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.